Internet survey on EpiPen adrenaline autoinjector usage in Japanese patients with a history of anaphylaxis

Little is known in Japan about anaphylaxis management during an episode and after the episode to prevent recurrence.

This study aimed to clarify the reality of anaphylaxis management by surveying individuals who had experienced an anaphylactic episode and attended a medical institution after the episode.

A general consumer panel was used to identify individuals ≥16 years (or child ≤15 years) with a history of anaphylaxis. Data were collected on the use of an adrenaline autoinjector at the time of the episode, attendance at a medical institution during and after the episode, and prescribing patterns for the adrenaline autoinjector.

Data were analyzed from 678 individuals (respondent [n = 552]; respondent on behalf of a child ≤15 years [n = 126]). Adrenaline autoinjector use at the time of the most recent anaphylactic episode was reported by approximately 7% of respondents, including by a subgroup with at least 2 previous anaphylactic episodes (n = 211). Only three-quarters of autoinjector users were prescribed another device at the medical institution they visited when anaphylaxis occurred. Among 349 respondents who visited a medical institution to prepare for recurrence, only 70 were prescribed another adrenaline autoinjector. Common reasons for nonprescription of another device were patients' lack of interest or physicians' lack of initiative.

There is a clear need to raise awareness and educate patients, parents, caregivers, and healthcare providers about anaphylaxis management.